Patents by Inventor Lori Friedman

Lori Friedman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MUTANT SELECTIVITY AND COMBINATIONS OF A PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUND AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
    Publication number: 20180280408
    Abstract: Methods and compositions are provided for treating hyperproliferative disorders in patients with a PI3K inhibitor, GDC-0032 as a single agent or in combination with chemotherapeutic agents.
    Type: Application
    Filed: February 14, 2018
    Publication date: October 4, 2018
    Applicant: Genentech, Inc.
    Inventors: Marcia Belvin, Lori Friedman, Deepak Sampath, Jeffrey Wallin
  • Methods of treating PR-positive, luminal A breast cancer with PI3K inhibitor, pictilisib
    Patent number: 10004748
    Abstract: Methods and compositions are provided for treating breast cancer in patients with a PI3K inhibitor, GDC-0941 in combination with an endocrine therapy agent.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: June 26, 2018
    Assignee: Genentech, Inc.
    Inventors: Mika K. Derynck, Lori Friedman, Steven Brian Gendreau, Sandra Milan
  • Methods and compositions for modulating estrogen receptor mutants
    Patent number: 9855270
    Abstract: Described herein are methods and compositions for treating an ER-related disease condition characterized by a mutation in the ESR1 gene by administering an estrogen receptor modulator. Also described herein are methods of treating hormone resistant-estrogen receptor (ER) positive breast cancers characterized by a mutation in the ESR1 gene by administering an estrogen receptor modulator.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: January 2, 2018
    Assignee: GENENTECH, INC.
    Inventors: Jeffrey J. Hager, James D. Joseph, Jing Qian, Nicholas D. Smith, Edna Chow Maneval, Debasish F. Roychowdhury, Lori Friedman, Deepak Sampath
  • METHODS OF TREATMENT WITH TASELISIB
    Publication number: 20160375033
    Abstract: Taselisib (GDC-0032) induces the degradation of mutant-p110 alpha protein. Methods for selecting patients with mutant PI3K tumors for treatment with taselisib are described.
    Type: Application
    Filed: June 28, 2016
    Publication date: December 29, 2016
    Applicant: Genentech, Inc.
    Inventors: Kyle Edgar, Lori Friedman, Deepak Sampath, Kyung Song, Ingrid Wertz, Timothy Wilson
  • COMBINATIONS OF A PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUND AND A CDK4/6 INHIBITOR COMPOUND FOR THE TREATMENT OF CANCER
    Publication number: 20160279142
    Abstract: Methods and compositions are provided for treating cancer in patients with a therapeutic combination comprising a therapeutically effective amounts of taselisib and palbociclib, or stereoisomers, geometric isomers, tautomers, or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: March 24, 2016
    Publication date: September 29, 2016
    Applicant: Genentech, Inc.
    Inventors: Lori Friedman, Michelle Nannini, Deepak Sampath, Jeffrey Wallin
  • Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
    Patent number: 9335320
    Abstract: Combinations of PI3K inhibitor compounds having Formula I and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hematopoietic malignancies.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: May 10, 2016
    Assignee: Genentech, Inc.
    Inventors: Allen J. Ebens, Jr., Lori Friedman
  • MUTANT SELECTIVITY AND COMBINATIONS OF A PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUND AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
    Publication number: 20160045515
    Abstract: Methods and compositions are provided for treating hyperproliferative disorders in patients with a PI3K inhibitor, GDC-0032 as a single agent or in combination with chemotherapeutic agents.
    Type: Application
    Filed: July 6, 2015
    Publication date: February 18, 2016
    Applicant: Genentech, Inc.
    Inventors: Marcia Belvin, Lori Friedman, Deepak Sampath, Jeffrey Wallin
  • METHODS OF TREATING PR-POSITIVE, LUMINAL A BREAST CANCER WITH PI3K INHIBITOR, PICTILISIB
    Publication number: 20150335650
    Abstract: Methods and compositions are provided for treating breast cancer in patients with a PI3K inhibitor, GDC-0941 in combination with an endocrine therapy agent.
    Type: Application
    Filed: May 20, 2015
    Publication date: November 26, 2015
    Applicant: Genentech, Inc.
    Inventors: Mika K. Derynck, Lori Friedman, Steven Brian Gendreau, Sandra Milan
  • METHODS AND COMPOSITIONS FOR MODULATING ESTROGEN RECEPTOR MUTANTS
    Publication number: 20150258099
    Abstract: Described herein are methods and compositions for treating an ER-related disease condition characterized by a mutation in the ESR1 gene by administering an estrogen receptor modulator. Also described herein are methods of treating hormone resistant-estrogen receptor (ER) positive breast cancers characterized by a mutation in the ESR1 gene by administering an estrogen receptor modulator.
    Type: Application
    Filed: March 12, 2015
    Publication date: September 17, 2015
    Applicant: GENENTECH, INC.
    Inventors: Jeffrey J. Hager, James D. Joseph, Jing Qian, Nicholas D. Smith, Edna Chow Maneval, Debasish F. ROYCHOWDHURY, Lori Friedman, Deepak Sampath
  • THERAPEUTIC COMBINATIONS WITH ESTROGEN RECEPTOR MODULATORS
    Publication number: 20150258080
    Abstract: Described herein are therapeutic combinations with estrogen receptor modulators for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Application
    Filed: March 12, 2015
    Publication date: September 17, 2015
    Applicant: Genentech, Inc.
    Inventors: Jeffrey J. Hager, Edna Chow Maneval, Nicholas D. Smith, Lori Friedman, Deepak Sampath
  • Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
    Patent number: 9107926
    Abstract: Methods and compositions are provided for treating hyperproliferative disorders in patients with a PI3K inhibitor, GDC-0032 as a single agent or in combination with chemotherapeutic agents.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: August 18, 2015
    Assignee: GENENTECH, INC.
    Inventors: Marcia Belvin, Lori Friedman, Deepak Sampath, Jeffrey Wallin
  • SCDs as modifiers of the p53 pathway and methods of use
    Patent number: 8771942
    Abstract: Human SCD genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SCD are provided.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: July 8, 2014
    Assignee: Exelixis, Inc.
    Inventors: Marcia Belvin, Helen Francis-Lang, Lori Friedman, Gregory D. Plowman, Timothy S. Heuer
  • MUTANT SELECTIVITY AND COMBINATIONS OF A PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUND AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
    Publication number: 20140044706
    Abstract: Methods and compositions are provided for treating hyperproliferative disorders in patients with a PI3K inhibitor, GDC-0032 as a single agent or in combination with chemotherapeutic agents.
    Type: Application
    Filed: June 7, 2013
    Publication date: February 13, 2014
    Inventors: Marcia Belvin, Lori Friedman, Deepak Sampath, Jeffrey Wallin
  • COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE
    Publication number: 20130345217
    Abstract: Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: August 28, 2013
    Publication date: December 26, 2013
    Applicant: Genentech, Inc.
    Inventors: Marcia Belvin, Lori Friedman, Klaus P. Hoeflich, Jeffrey Wallin
  • COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES
    Publication number: 20130330765
    Abstract: Combinations of PI3K inhibitor compounds having Formula I and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hematopoietic malignancies. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: August 15, 2013
    Publication date: December 12, 2013
    Applicant: Genentech, Inc.
    Inventors: Allen J. Ebens, JR., Lori Friedman
  • Combinations of phosphoinositide 3-kinase inhibitor compounds chemotherapeutic agents, and methods of use
    Patent number: 8604014
    Abstract: Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: December 10, 2013
    Assignees: Genentech, Inc., F. Hoffmann-La Roche AG
    Inventors: Marcia Belvin, Lori Friedman, Klaus Hoeflich, Deepak Sampath, Ulka Vijapurkar, Jeffrey Wallin, Leisa Johnson, Mallika Singh, Sonal Patel
  • Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
    Patent number: 8536161
    Abstract: Combinations of PI3K inhibitor compounds having Formula I and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hematopoietic malignancies. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: March 11, 2010
    Date of Patent: September 17, 2013
    Assignee: Genentech, Inc.
    Inventors: Allen J. Ebens, Jr., Lori Friedman
  • RORS as modifiers of the p21 pathway and methods of use
    Patent number: 8426147
    Abstract: Human ROR genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of ROR are provided.
    Type: Grant
    Filed: December 1, 2008
    Date of Patent: April 23, 2013
    Assignee: Exelixis, Inc.
    Inventors: Helen Francis-Lang, Lori Friedman, Thomas Kidd, Siobhan Roche, Haiguang Zhang
  • MAP3Ks as modifiers of the p53 pathway and methods of use
    Patent number: 8268548
    Abstract: Human MAP3K genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MAP3K are provided.
    Type: Grant
    Filed: April 18, 2007
    Date of Patent: September 18, 2012
    Assignee: Exelixis, Inc.
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danix Li, Roel P. Funke
  • Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
    Patent number: 8247397
    Abstract: Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: August 21, 2012
    Assignees: Genentech, Inc., F. Hoffman-La Roche AG
    Inventors: Marcia Belvin, Lori Friedman, Klaus Hoeflich, Deepak Sampath, Ulka Vijapurkar, Jeffrey Wallin, Leisa Johnson, Mallika Singh, Sonal Patel